Regenerative medicine and gene therapy offer transformative potential in addressing global health challenges, particularly noncommunicable and rare diseases. These innovative treatments can shift healthcare from symptom management to curative, personalized solutions, but face high upfront R\&D and regulatory costs. Countries like Japan, the UAE, and Australia demonstrate how digital readiness, regulatory agility, and targeted investment can accelerate adoption. AI, CRISPR, and stem cell innovations are enabling breakthroughs, but affordability remains a key hurdle. Cross-sector collaboration is essential to reduce costs, scale access, and build sustainable, future-ready healthcare systems.

Join for free to read